INAL RESEARCH Effectiveness of next-generation sequencing for patients with advanced non-small-cell lung cancer: a population-based registry study

被引:5
|
作者
Kang, D. -W. [1 ]
Park, S. -K. [2 ]
Yu, Y. L. [3 ]
Lee, Y. [4 ]
Lee, D. H. [5 ]
Kang, S. [3 ,6 ,7 ,8 ]
机构
[1] Sungkyunkwan Univ, Sch Pharm, Suwon, South Korea
[2] Catholic Univ Korea, Coll Pharm, Bucheon, South Korea
[3] Natl Canc Ctr, Ctr Gynecol Canc, Res Inst & Hosp, Goyang, South Korea
[4] Natl Canc Ctr, Dept Internal Med, Goyang, South Korea
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[6] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc Control & Policy, Goyang, South Korea
[7] Natl Canc Ctr, Res Inst & Hosp, Ctr Gynecol Canc, 323 Ilsan Ro, Goyang Si, Gyeonggi Do, South Korea
[8] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc Control & Policy, 323 Ilsan Ro, Goyang Si, Gyeonggi Do, South Korea
关键词
next-generation sequencing; single-gene testing; non-small-cell lung cancer; distant metastasis; real-world evidence;
D O I
10.1016/j.esmoop.2023.102200
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Despite the growing use of next-generation sequencing (NGS) in the management of advanced non-smallcell lung cancer (NSCLC), there is little evidence that its use leads to improved clinical outcomes. This study aimed to compare the effectiveness of NGS with that of single-gene testing (SGT) alone in patients with advanced NSCLC. Materials and methods: This was a retrospective cohort study conducted on patients diagnosed with advanced lung adenocarcinoma between 2017 and 2018 from a nationwide, population-based database. We identified patients who had SGT exclusively (SGT group) or underwent upfront NGS or NGS following SGT as an initial evaluation (NGS group). Patients were followed up until death or the end of the study (31 December 2019). The adjusted hazard ratio (aHR) for death was estimated using the Cox proportional hazards model. The factors affecting the adoption of NGS were identified. Results: Of 8566 patients diagnosed with advanced lung adenocarcinoma, 402 and 6932 patients were assigned to the NGS and SGT groups, respectively. More NGS was carried out in younger patients, those with higher incomes, and those living in urban areas. After balancing these confounders through matching, no difference was observed in the median overall survival and risk of death between the NGS and SGT groups [18.5 versus 19.7 months, log-rank P 1/4 0.783; aHR 0.98, 95% confidence interval (CI) 0.84-1.14, respectively]. Only in a subgroup for whom epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) inhibitors were not indicated, NGS was associated with better survival outcomes (14.1 versus 9.0 months, log-rank P 1/4 0.006; aHR 0.82, 95% CI 0.69-0.97). Conclusions: In the real world, NGS for all-comers in patients with advanced NSCLC did not increase survival outcomes. When health care resources to support equal access to NGS are limited, upfront SGT followed by NGS may be a more efficient strategy
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Real World Applications of Next-Generation Sequencing of Non-Small Cell Lung Cancer in the Veteran Population
    Kratz, J.
    Harmon, G.
    Kosoff, D.
    Wubben, D.
    Laughlin, R.
    Traynor, A.
    Deming, D.
    Burkard, M.
    Leal, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S615 - S615
  • [22] Mutational profile of non-small cell lung cancer by targeted next-generation sequencing in the Mexican population
    Socca, Giovanny
    Alaez, Carmen
    Hernandez-Pedro, Norma
    Barrios-Bernal, Pedro A.
    Carrillo-Sanchez, Karol
    Aviles, Alejandro
    Arrieta, Oscar
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : S24 - S25
  • [23] Budget impact analysis of next-generation sequencing versus sequential single-gene testing in Japanese patients with advanced non-small-cell lung cancer
    Matsuda, Hiroyuki
    Ogawa, Toru
    Sadatsuki, Yasunari
    Tsujino, Toshiaki
    Wada, Shingo
    Kim, Seok-Won
    Hatanaka, Yutaka
    RESPIRATORY INVESTIGATION, 2023, 61 (01) : 61 - 73
  • [24] Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments
    Zugazagoitia, Jon
    Rueda, Daniel
    Carrizo, Nuria
    Enguita, Ana Belen
    Gomez-Sanchez, David
    Diaz-Serrano, Asuncion
    Jimenez, Elisabeth
    Merida, Antonio
    Calero, Rosa
    Lujan, Ricardo
    De Miguel, Eduardo
    Gamez, Pablo
    Diaz-Hellin, Vicente
    Antonio Nunez, Juan
    Iglesias, Lara
    Ferrer, Irene
    Paz-Ares, Luis
    Ponce-Aix, Santiago
    CLINICAL LUNG CANCER, 2018, 19 (01) : 65 - +
  • [25] Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non-Small-Cell Lung Cancer
    Remon, Jordi
    Lacroix, Ludovic
    Jovelet, Cecile
    Caramella, Caroline
    Howarth, Karen
    Plagnol, Vincent
    Rosenfeld, Nitzan
    Morris, Clive
    Mezquita, Laura
    Pannet, Chloe
    Ngocamus, Maud
    Le Pechoux, Cecile
    Adam, Julien
    Grecea, Alina-Miruna
    Planchard, David
    Vassal, Gilles
    Benitez, Jose Carlos
    Gazzah, Anas
    Green, Emma
    Soria, Jean-Charles
    Besse, Benjamin
    JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 14
  • [26] Comprehensive Next-Generation Sequencing-Guided Targeted Therapy Correlates with Survival in Non-Small-Cell Lung Cancer
    Wang, Z.
    Lu, B.
    Liu, G.
    Xu, T.
    Jiang, L.
    Chen, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S944 - S945
  • [27] NTRK1 fusion identified by capture-based next-generation sequencing in non-small-cell lung cancer.
    Zhao, Ruiying
    Xiang, Chan
    Dong, Nan
    Guo, Lianying
    Ma, Shengji
    Han, Yuchen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Treatment patterns in stage III non-small-cell lung cancer patients: a population-based study using German cancer registry data
    Bedir, Ahmed
    Mehrotra, Sneha
    Gnuechtel, Jessica
    Vordermark, Dirk
    Medenwald, Daniel
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (17) : 15489 - 15497
  • [29] Effectiveness of nationwide insurance coverage for next-generation sequencing in advanced non-small cell lung cancer: A real-world data study.
    Kang, Dong-Won
    Park, Sun-Kyeong
    Yu, Ye Lee
    Lee, Dae Ho
    Kang, Sokbom
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] A single center experience with next generation sequencing (NGS) for the care of advanced non-small-cell lung cancer (NSCLC).
    Rangachari, Deepa
    VanderLaan, Paul A.
    Le, Xiuning
    Folch, Erik
    Kent, Michael S.
    Gangadharan, Sidharta P.
    Majid, Adnan
    Haspel, Richard L.
    Joseph, Loren
    Huberman, Mark
    Costa, Daniel Botelho
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)